INSIGHTS ON CLINICAL TRIAL PARTNERING

• Insights From The EACT Clinical Trials Site Personnel Webinar

  Collaboration among clinical research stakeholders is breaking financial barriers to support equitable trial access.

• Participant Payments: Navigating Modern Studies

  To address the challenges of disbursing clinical trial participant payments globally, sponsors need region-specific payment solutions that navigate local laws and banking systems.

• Optimizing Site Activation To Accelerate Clinical Trials

  Clinical trial site activation delays are a major bottleneck in drug development, hampering trial timelines and funding flows. To reverse this trend, site-focused solutions are being prioritized.

• A Guide To Patient Reimbursements And Payments

  Delayed or inadequate payments can harm patient retention and site efficiency. Learn how sponsors can mitigate financial toxicity, streamline reimbursement, and ensure a positive experience for all involved.

• How Smaller Biotechs Are Rethinking CRO Relationships Post-Pandemic

  3/9/2026

  Smaller biotechs are rethinking CRO partnerships, valuing speed, scientific access, flexibility, and transparent pricing over scale — driven by pandemic lessons and a sharper focus on operational fit.

• Driving Attendance At Investigators' Meetings In Clinical Research

  2/11/2026

  How do planning choices, logistics, and format decisions influence meeting attendance and engagement?

• What Sponsors Need To Know Before They Get To The IRB & IBC

  5/13/2026

  Gene therapy requires early, rigorous safety planning and command of pediatric and biosafety rules. Early committee engagement reduces delays and strengthens high‑stakes trials.

• Why Site Training Still Slows Site Activation

  5/11/2026

  Effective site training relies on clear, accessible, up-to-date materials that reflect real workflows — keeping sites aligned, compliant, and confident throughout the study lifecycle.

• Taking Research In-House With CRIO: SciTech's Multi-Center Phase 1 Study

  1/6/2025

  Explore the success story of an early-stage clinical pharmaceutical company that effectively navigated funding constraints when conducting its Phase 1 study without a third-party CRO.